English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives  All  HIV /hepatitis  C  virus ( HCV )‐coinfected patients with chronic  HCV  infection and ≥  F 2 fibrosis should be considered for  HCV  therapy. This study aimed to determine the rate of  HCV  treatment uptake among coinfected patients in Europe.    Methods   EuroSIDA  patients with viraemic  HCV  infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in  HCV  treatment uptake.    Results  A total of 1984 patients were included in the study, with a median follow‐up time of 168 months [interquartile range ( IQR ) 121–204 months]. To date, 501 (25.3%)  HIV / HCV ‐coinfected patients have received  HCV  therapy. Treatment incidence rose from 0.33 [95% confidence interval ( CI ) 0.16–0.50] per 100 person‐years of follow‐up ( PYFU ) in 1998 to 5.93 (95%  CI  4.49–7.38) in 2007, falling to 3.78 (95%  CI  2.50–5.07) in 2009. After adjustment,  CD4  cell count > 350 cells/μL [incidence rate ratio ( IRR ) 1.33 (95% CI 1.06–1.67)  vs.   CD4  count 200−350 cells/μL] and ≥ F 2 liver fibrosis [ IRR  1.60 (95%  CI  1.14–2.25;  P  = 0.0065)  vs.  <  F 2 fibrosis] were predictors of anti‐ HCV  treatment initiation. However, 22% of patients who remain untreated for  HCV , with fibrosis data available, had ≥ F 2 fibrosis and should have been considered for treatment, while only 36% of treated patients had ≥ F 2 fibrosis.    Conclusions  Although treatment incidence for  HCV  has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA